|本期目录/Table of Contents|

[1]段 松.前列腺癌组织中Skp2的表达及其与前列腺癌术后复发的关系[J].医学研究与战创伤救治(原医学研究生学报),2016,18(01):47-50.[doi:10.3969/j.issn.1672-271X.2016.01.014]
　DUAN Song..The expression of Skp2 in prostate cancer and its relationship with postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(01):47-50.[doi:10.3969/j.issn.1672-271X.2016.01.014]
点击复制

前列腺癌组织中Skp2的表达及其与前列腺癌术后复发的关系()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第18卷
期数:
2016年01期
页码:
47-50
栏目:
出版日期:
2016-01-20

文章信息/Info

Title:
The expression of Skp2 in prostate cancer and its relationship with postoperative recurrence
作者:
段 松
404000 重庆,重庆三峡中心医院病理科
Author(s):
DUAN Song.
Department of Pathological, the Three Gorges Central Hospital of Chongqing， Chongqing 404000, China
关键词:
前列腺癌; S期激酶相关蛋白2; 复发率; 生存率
Keywords:
prostate cancer;  Skp2;  recurrence rate;  survival rate
分类号:
R737.25
DOI:
10.3969/j.issn.1672-271X.2016.01.014
文献标志码:
A
摘要:
目的 研究S期激酶相关蛋白2(S-phase kinase associated protein 2, Skp2)在前列腺癌患者中的表达及其与前列腺癌术后复发的关系。方法 选择2010年6月- 2012年6月接受手术的前列腺癌86例作为观察组，同时选取良性前列腺增生25例作为对照组，检测两组前列腺组织中Skp2的mRNA水平和Skp2蛋白的表达，根据Skp2表达情况将观察组 分为阳性组和阴性组，分析Skp2表达与临床病理特征及术后复发的关系。结果 与对照组相比，观察组前列腺癌组织中Skp2 mRNA和Skp2蛋白的表达均显著升高（P<0.05）。观察组 Skp2阴性35例的1、2、3年复发率为8.57%、25.71%、31.43%，显著低于Skp2阳性51例的27.45%、39.22%、49.02%（P<0.05）；Skp2阴性患者1、2、3年生存率分别为97.14%、91.43% 、82.86%，显著高于Skp2阳性患者的90.19%、84.31%、70.59%（P<0.05）。结论 前列腺癌组织中Skp2 mRNA和Skp2蛋白的高水平表达与前列腺癌组织分型、临床分期、肿瘤浸润程 度以及淋巴结转移有一定关系，可能是前列腺癌发展的重要机制之一。
Abstract:
Objective To study the expression of Skp2 in prostate cancer and its relationship with the recurrence of prostate cancer. Methods 86 cases of patients diagnosed with prostate cancer and received operation in our hospital from June 2010 to June 2012 were randomly selected as observation group. At the same time, 25 cases patients with benign prostatic hyperplasia were selected as control group. Skp2 mRNA level in the two groups were determined by real-time quantitative PCR. Skp2 protein level was analyzed by immunohistochemistry. According to Skp2 level, 86 cases of patients were divided into Skp2 positive group and Skp2 negative group. The relationship between Skp2 protein level and clinical pathological features and postoperative recurrence in Skp2 positive group and Skp2 negative group were analyzed. Results Compared with the control group, Skp2 mRNA and protein levels in the prostate cancer tissues of the observation group increased significantly (P<0.05). 1, 2 and 3 year cumulative recurrence rate in the Skp2 negative patients were 8.57%, 25.71 and 31.43%, while 27.45%, 39.22% and 49.02% in Skp2 positive patients. The cumulative recurrence rate of Skp2 protein-negative patients was significantly lower than that of Skp2 positive patients (P<0.05). 1, 2 and 3 year cumulative survival rate in the Skp2 protein-negative patients were 97.14%, 91.43% and 82.86%, while 90.19%, 84.31% and 70.59% in Skp2 positive patients. The cumulative survival rate of Skp2 protein-negative patients was significantly higher than that of Skp2 positive patients (P<0.05). Conclusion The high expression of Skp2 mRNA and protein in prostate cancer tissues are closely related to types, clinical stage, tumor invasion and lymph node metastasis of prostate cancer, which may be one of the important mechanism of prostate cancer development.

参考文献/References:

[1]Kelly BD, Miller N, Sweeney KJ, et al. A circulating microRNA signature as a biomarker for prostate cancer in a high risk group[J]. J Clin Med. 2015,4 (7):1369-1379.
[2]Gohil K. Exciting therapies ahead in prostate cancer[J].P T, 2015,40(8):530-531.
[3]Singh P, Pal SK, Alex A, et al. Development of PROSTVAC immunotherapy in prostate cancer[J]. Future Oncol, 2015,11(15):2137-2148.
[4]Abuadas MH, Petro-Nustas W, Albikawi ZF. Predictors of participation in prostate cancer screening among older men in Jordan[J]. Asian Pac J Cancer Prev, 2015,16(13):5377-5383.
[5]Bashir MN.Epidemiology ofprostate cancer[J]. Asian Pac J Cancer Prev, 2015, 16(13):5137-5141.
[6]Ersekerci E, Sofikerim M, Taheri S, et al.Genetic polymorphism in sex hormone metabolism and prostate cancer risk[J].Genet Mol Res, 2015,14(3):7326-7334.
[7]Yang WR, Wang Y, Wang Y, et al. mTOR is involved in 17β-estradiol-induced, cultured immature boar sertoli cell proliferation via regulating the expression of Skp2, CCND1, and CCNE1[J]. MolReprod Dev, 2015, 82(4):305-314.
[8]王 琦, 蒋敬庭, 吴昌平. Skp2在前列腺癌中的研究进展[J]. 医学综述. 2011, 17(7):1004-1007.
[9]Moro L, Arbini AA, Marra E, et al.Up-regulation of Skp2 after prostate cancer cell adhesion to basement membranes results in BRCA2 degradation and cell proliferation[J]. J Biol Chem, 2006, 281(31):22100-22107.
[10]张振宇, 张宇锋, 张宏伟. Sox2在人前列腺癌中的表达及其临床意义[J]. 国际肿瘤学杂志，2014,41(11): 875-878.
[11]叶定伟，顾成元，朱 耀. NCCN前列腺癌临床实践指南亚洲共识(V2.2013版)要点解读与分析[J]. 中华外科杂志, 2015, 53(1): 63-57.
[12]徐叶青，郭剑明，朱延军, 等. 不同PSA水平的国人首次前列腺穿刺活检所需穿刺针数的研究[J].肿瘤防治研究, 2014, 41(2):124-127.
[13]夏维木, 刘定益, 周文龙, 等. 新辅助治疗后RT-PCR对前列腺癌盆腔淋巴结微转移的诊断价值[J]. 东南国防医药, 2012,14(5): 399-401.
[14]翟金盛, 王晓玲, 王 颖. 前列腺癌患者社会支持和抑郁状况调查及相关性分析[J]. 东南国防医药, 2015,17(1): 67-69..
[15]Chan CH, Morrow JK, Zhang S, et al. Skp2: a dream target in the coming age of cancer therapy[J]. Cell Cycle, 2014, 13(5):679-680.
[16]Cheng H, Meng J, Wang G, et al.Skp2 regulates subcellular localization of PPARγ by MEK signaling pathways in human breast cancer[J]. Int J Mol Sci, 2013, 14(8):16554-16569.
[17]Wang Z, Gao D, Fukushima H, et al.Skp2: a novel potential therapeutic target for prostate cancer[J]. Biochim Biophys Acta, 2012, 1825(1):11-17.
[18]Shapira M, Ben-Izhak O, Slotky M, et al. Expression of the ubiquitin ligase subunit cyclin kinase subunit 1 and its relationship to S-phase kinase protein 2 and p27Kip1 in prostate cancer[J]. J Urol, 2006, 176(5):2285-2289.
[19]邢 岳, 王纾宜, 许祖德. Skp2在鼻型NK/T细胞淋巴瘤中的表达及临床意义[J]. 复旦学报（医学版）, 2014, 41(1): 60-65.
[20]Bochis OV, Irimie A, Pichler M, et al. The role of Skp2 and its substrate CDKN1B (p27) in colorectal cancer[J]. J Gastrointestin Liver Dis, 2015, 24 (2):225-234.
[21]Zheng WQ, Zheng JM, Ma R, et al.Relationship between levels of Skp2 and P27 in breast carcinomas and possible role of Skp2 as targeted therapy[J]. Steroids, 2005, 70(11): 770-774.
[22]Wei S, Chu PC, Chuang HC, et al. Targeting the oncogenic E3 ligase Skp2 in prostate and breast cancer cells with a novel energy restriction-mimetic agent[J]. PLoS One, 2012, 7(10):e47298.

相似文献/References:

[1]翟金盛,王晓玲,王 颖.前列腺癌患者社会支持和抑郁状况调查及相关性分析[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):67.[doi:10.3969/j.issn.1672-271X.2015.01.022]
　ZHAI Jin-sheng,WANG Xiao-ling,WANG Ying..Social support， depression and their correlation in the prostate cancer patients[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(01):67.[doi:10.3969/j.issn.1672-271X.2015.01.022]
[2]罗伟,吴静,方克伟.C-反应蛋白与前列腺癌相关性的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):516.[doi:10.3969/j.issn.1672-271X.2020.05.014]
　LUO Wei,WU Jing,FANG Ke-wei.Research progress on the relationship between C-reactive protein and prostate cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(01):516.[doi:10.3969/j.issn.1672-271X.2020.05.014]
[3]高杰,丁留成,卫中庆.脂质代谢在去势抵抗性前列腺癌中的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(02):169.[doi:10.3969/j.issn.1672-271X.2021.02.013]
　GAO Jie,DING Liu-cheng,WEI Zhong-qing.Research progress of lipid metabolism in castration-resistant prostate cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(01):169.[doi:10.3969/j.issn.1672-271X.2021.02.013]
[4]黄明清,翁雨亭,方克伟.雌激素受体的生物学功能及其在骨骼肌发育和前列腺癌中作用的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2022,24(2):172.[doi:10.3969/j.issn.1672-271X.2022.02.013]
　HUANG Ming-qing,WENG Yu-ting,FANG Ke-wei.Advances in the study of the biological function of estrogen receptor and its role in skeletal muscle development and prostate cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(01):172.[doi:10.3969/j.issn.1672-271X.2022.02.013]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2016-01-20